Ed­i­to­r­i­al: With Califf con­firmed, FDA needs to re­turn to pri­or­i­ties lost to the pan­dem­ic and im­prove its mes­sag­ing

The pan­dem­ic is by no means over, and the FDA will sure­ly con­tin­ue to pri­or­i­tize the nec­es­sary EUAs for ad­di­tion­al ther­a­pies and tar­get­ed vac­cines as well as oth­er mea­sures to bring down the bal­loon­ing death toll.

In fact, the first big item on new­ly Sen­ate-con­firmed FDA com­mish Rob Califf’s plate will be the or­deal around Pfiz­er’s vac­cine for the youngest chil­dren.

The FDA last week rubbed egg on its own face by not on­ly call­ing for Pfiz­er to sub­mit da­ta, but sched­ul­ing an ad­comm to re­view the da­ta on this low­est-dose vac­cine, con­tem­plat­ing start­ing with two dos­es be­fore wait­ing for da­ta on a third.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER